Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 10/20 | 0.53 |
| ▸ | CDK8 | P49336 | 10/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27834290 | 1.00 | CCNC (0.53) | CCNCCDK8HRH4HRH3TRPV1 | |
| SCHEMBL18228251 | 1.00 | CCNC (0.53) | CCNCCDK8HRH4HRH3TRPV1 | |
| SCHEMBL15413225 | 0.93 | BTK (0.53) | CCNCCDK8HRH4TRPV1BTK | |
| SCHEMBL4334757 | 0.92 | TRPV1 (0.51) | CCNCCDK8TRPV1 | |
| SCHEMBL28788119 | 0.89 | TRPV1 (0.47) | CCNCCDK8TRPV1BTK | |
| SCHEMBL20445941 | 0.85 | CCNC (0.57) | CCNCCDK8HRH4HRH3BTK | |
| SCHEMBL1588740 | 0.83 | JAK3 (0.55) | BTK | |
| SCHEMBL28219652 | 0.83 | JAK3 (0.55) | BTK | |
| SCHEMBL16629090 | 0.83 | JAK3 (0.55) | BTK | |
| SCHEMBL16620125 | 0.82 | CCNC (0.67) | CCNCCDK8HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3355699-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE INC (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE, INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| EP-3355699-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | OncoTherapy Science, Inc. (JP) | 2018-08-08 | — | — | EP | disclosed |
| WO-2015049325-A1 | THERAPEUTIC INHIBITORS OF CDK8 AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| US-20150045255-A1 | Endometrial Phase or Endometrial Cancer Biomarkers | WALFISH, PAUL (CA) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | SUV39H2, SUV39H1, EZH1 | CCNC 2670/4885CDK8 1225/4885HRH4 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.